Race Oncology expands share count after option conversion

Race Oncology Ltd has applied for the quotation of 122,829 new fully paid ordinary shares (ASX: RAC) following the exercise of options. The conversion occurred on November 6, 2025, with an issue price of AUD 1.25000000 per security, representing a cash consideration for the newly issued shares.

The options converted were part of the RACAAA class, which were expiring on May 29, 2026, with an exercise price of AUD 1.25. After this conversion, the total number of quoted ordinary fully paid shares for Race Oncology Ltd will increase to 176,929,929. The newly quoted securities will rank equally in all respects with the existing issued securities of that class from their issue date.

While 122,829 options were converted, a significant number of options in the RACAAA class, specifically 16,654,575, remain unquoted. The company also maintains various other unquoted convertible securities, with expiration dates ranging from 2025 to 2029 and exercise prices varying from AUD 1.32 to AUD 4.90.